Clinical Trials | January 24, 2022
RaphaCure partners with Madhavbaug for cardiac healthcare services
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
The country is sixth among the most affected countries by active cases
UCB plans to submit regulatory applications in Q3 2022
Go-ahead for pivotal clinical trial which is expected to commence by March
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
However, these won’t be available at the nearest chemist store soon
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Subscribe To Our Newsletter & Stay Updated
